Daunomycin immunoliposomes

Plasma clearance (Cl), blood-brain barrier permeability surface area product (PS) and accumulation as % injected dose detected in brain tissue (%ID tissue) at 1 h after administration. Results show free [ H]-daunomycin (Daunomycin), [ H]-daunomycin encapsulated in conventional liposomes (Liposomes), sterically stabilized liposomes (PEG-liposomes), immunoliposomes (29 0X26, where 29 designates the number of 0X26 mAb conjugated per liposome) and control immunoliposomes where the 0X26 mAb was replaced by a non-specific isotype control antibody (IgG2a). Values are means SEM of n = 3 experiments. 

In conclusion, the use of an immunoliposome-based drug delivery system allows for targeted delivery of a small molecule such as daunomycin or plasmids to the rat brain in vivo. Further experiments will be needed to clarify the subcellular routes and compartments involved in the transcytosis mechanism, as well as the eventual release mechanism in the target cell. 

Huwyler, J., Yang, J., and Pardridge, W. M. (1997),Targeted delivery of daunomycin using immunoliposomes Pharmacokinetics and tissue distribution in the rat, J. Pharmacol. Exp. Then, 282,1541-1546. 

Schnyder,A.,Krahenbuhl,S.,Drewe, J.,and Huwyler, (2005),Targeting of daunomycin using biotinylated immunoliposomes Pharmacokinetics, tissue distribution and in vitro pharmacological effects,/. Drug Targeting., 13, 325-335. 

---